Cardioprotective effect of κ1-opioid receptor activation and role of cAMP in its realization

Bulletin of Experimental Biology and Medicine

Volumn 143, Issue 1, 2007, Pages 22-25

  Lasukova, T V ^a   Maslov, L N ^a   Platonov, A A ^a   Guzarova, N V ^a   Lishmanov, Yu B ^a  

^a Russian Academy of Medical Sciences   (Russian Federation)

Author keywords

1 opioidreceptors; cAMP; Ischemia reperfusion; Isolated perfused heart

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; CREATINE KINASE; CYCLIC AMP; KAPPA OPIATE RECEPTOR AGONIST; OPIATE RECEPTOR; ANTIARRHYTHMIC AGENT; KAPPA OPIATE RECEPTOR; KAPPA(1) OPIOID RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SELECTIVITY; ENZYME RELEASE; HEART ARRHYTHMIA; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; INCIDENCE; INHIBITION KINETICS; ISOLATED HEART; MALE; NONHUMAN; PROTEIN INTERACTION; RAT; TIME; ANIMAL; DRUG POTENTIATION; HEART MUSCLE; METABOLISM; PHYSIOLOGY; REPERFUSION INJURY; WISTAR RAT;

RATTUS;

3,4-DICHLORO-N-METHYL-N-(2-(1-PYRROLIDINYL)-CYCLOHEXYL)-BENZENEACETAMIDE, (TRANS)-ISOMER; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; CREATINE KINASE; CYCLIC AMP; MALE; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; MYOCYTES, CARDIAC; RATS; RATS, WISTAR; RECEPTORS, OPIOID, KAPPA;

EID: 34249042097     PISSN: 00074888     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10517-007-0007-0     Document Type: Article

References (13)

1. T. V. Lasukova, A. V. Krylatov, L. N. Maslov, et al., Pat. Fisiol. Eksper. Ter., No. 3, 12-15 (2004).
2. L. N. Maslov, Yu. B. Lishmanov, N. V. Solenkova, et al., Eksper. Klin. Farmakol., 68, No. 1, 25-29 (2005).
3. K. A. Aitchison, G. F. Baxter, M. M. Awan, et al., Basic Res. Cardiol., 95, No. 1, 1-10 (2000).
4. J. S. Bian, J.-M. Pei, Ch-S. Cheung, et al., J. Mol. Cell. Cardiol., 32, No. 8, 1415-1427 (2000).
5. C. Ela, J. Barg, Z. Vogel, et al., Ibid., 29, No. 2, 711-720 (1997).
6. R. A. Lahti, M. M. Mickelson, J. M. McCall, and P. F. Von Voigtlander, Eur. J. Pharmacol., 109, No. 2, 281-284 (1985).
7. L. N. Maslov and Y. B. Lishmanov, Clin. Exp. Pharmacol. Physiol., 22, No. 11, 812-816 (1995).
8. J. N. Peart, E. R. Gross, and G. J. Gross, J. Cardiovasc. Pharmacol., 43, No. 3, 410-415 (2004).
9. S. Wu, H. Y. Li, and T. M. Wong, Circ. Res., 84, No. 12, 1388-1395 (1999).
10. X. C. Yu, H. Y. Li, H. X. Wang, and T. M. Wong, J. Mol. Cell. Cardiol., 30, No. 2, 405-413 (1998).
11. X. C. Yu, H. X. Wang, J. M. Pei, and T. M. Wong, Ibid., 31, No. 10, 1809-1819 (1999).
12. W. M. Zhang, W. Q. Jin, and T. M. Wong, Ibid., 28, No. 7, 1547-1554 (1996).
13. R. Zimlichman, D. Gefel, H. Eliahou, et al., Circulation, 93, No. 5, 1020-1025 (1996).